GenSight Biologics Announces the Closing of its €1.0 Million Fundraising Supported by Existing Shareholders

GenSight Biologics Announces a Successful €1.0 Million Fundraising Supported by Existing Shareholders

GenSight Biologics Reports Cash Position as of September 30, 2026

GenSight Biologics Reports Interim Financial Results for the First Half of 2026 and Provides Business Updates

GenSight Biologics Provides September 2026 Business Updates

GenSight Biologics Reports Cash Position as of June 30, 2026, and Provides Business Updates

GenSight Biologics Announces the Filing of its 2025 Universal Registration Document

GenSight Biologics Reports Cash Position and Revenue from Early Access Program as of March 31, 2026

GenSight Biologics Confirms Definitive Full-Year 2025 Consolidated Financial Results Are in Line with Estimates

GenSight Biologics Reports Estimated Full-Year Consolidated Financial Results for 2025